Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ultragenyx Pharmaceutical

35.37
+1.534.52%
Post-market: 35.500.1300+0.37%18:46 EDT
Volume:570.89K
Turnover:19.96M
Market Cap:3.27B
PE:-5.63
High:35.42
Open:33.53
Low:33.53
Close:33.84
Loading ...

Ultragenyx Pharmaceutical Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Feb

Ultragenyx Pharmaceutical Q4 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
14 Feb

Ultragenyx: Q4 Earnings Snapshot

Associated Press Finance
·
14 Feb

Ultragenyx Pharmaceutical Inc - 2025 Financial Guidance: Total Revenue Between $640 Million to $670 Million

THOMSON REUTERS
·
14 Feb

Ultragenyx Pharmaceutical Q4 2024 GAAP EPS $(1.39) Misses $(1.29) Estimate, Sales $164.877 Miss $155.393M Estimate

Benzinga
·
14 Feb

BRIEF-Ultragenyx Q4 EPS USD -1.39 Vs. IBES Estimate USD -1.29

Reuters
·
14 Feb

Ultragenyx Q4 Operating Expenses USD 287 Million

THOMSON REUTERS
·
14 Feb

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

GlobeNewswire
·
14 Feb

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

GlobeNewswire
·
13 Feb

Frank Sands Reduces Stake in Ultragenyx Pharmaceutical Inc.

GuruFocus
·
13 Feb

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

GlobeNewswire
·
07 Feb

Ultragenyx Pharmaceutical Presents New Data for UX111 Gene Therapy, Expects FDA Approval Decision in H2

MT Newswires Live
·
05 Feb

Ultragenyx announces new data on UX111 AV gene therapy

TIPRANKS
·
05 Feb

Ultragenyx Pharmaceutical Inc - Pdufa Decision and Potential U.S. Launch Expected in H2 2025

THOMSON REUTERS
·
05 Feb

Ultragenyx Pharmaceutical Inc - Mitt Group Shows +22.7 Point Treatment Effect in Bayley-Iii Cognitive Score

THOMSON REUTERS
·
05 Feb

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

GlobeNewswire
·
05 Feb

Wedbush Trims Price Target on Ultragenyx Pharmaceutical to $47 From $48, Keeps Neutral Rating

MT Newswires Live
·
23 Jan

Ultragenyx Pharma Price Target Maintained With a $118.00/Share by Cantor Fitzgerald

Dow Jones
·
23 Jan

Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?

Zacks
·
22 Jan

U.S. RESEARCH ROUNDUP- Apple, Murphy USA, UnitedHealth

Reuters
·
21 Jan